Vitamin B6, Vitamin E and Folic Acid: study protocols
9 study groups took Vitamin B6 together with Vitamin E and Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin B6
9 study groups in 7 studies say how much Vitamin B6 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 33% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mcg to 1 mg | 2 |
| 1 mg to 2.5 mg | 1 |
| 2.5 mg to 5 mg | 0 |
| 5 mg to 10 mg | 1 |
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 1 |
| 50 mg to 100 mg | 1 |
Dose per serving from research: Vitamin E
7 study groups in 5 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 57% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg or less | 1 |
| 10 mg to 25 mg | 0 |
| 25 mg to 50 mg | 4 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 0 |
| over 250 mg | 1 |
Dose per serving from research: Folic Acid
9 study groups in 7 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mcg to 1 mg, 44% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 3 |
| 500 mcg to 1 mg | 4 |
| 1 mg to 2.5 mg | 0 |
| 2.5 mg to 5 mg | 2 |
Commonly used together
9 of 9 study groups took Vitamin B6, Vitamin E and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 8 |
| Vitamin C | 8 |
| Riboflavin | 5 |
| Thiamine | 4 |
9 study groups
| Study | |||||
|---|---|---|---|---|---|
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 2.2 mg | 10 mg | 400 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 25 mg | 30 mg | 800 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin without vitamin A · HIV-positive pregnant Tanzanian women | 25 mg | 30 mg | 800 mcg | — | — |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MVB · Patients with type 2 diabetes | 10 mg | 100 mg | 1 mg | 120 days | — |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1 mg | 40 mg | 400 mcg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1 mg | 40 mg | 400 mcg | 24 weeks | 201 |
| Supplementation with antioxidant micronutrients in pregnant women with obesity: a randomized controlled trial 2024 · Intervention group · Pregnant women with obesity (BMI ≥30 kg/m²) | 18 mg | — | 800 mcg | — | 64 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 50 mg | 800 IU | 5 mg | 2 weeks | 24 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 100 mg | 300 mg | 5 mg | 2 years | 47 |